The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency

ConditionsOveractive Bladder Vitamin D Deficiency

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

AgeUp to 18

SponsorTarik Emre Sener

About this trial

The primary aim of this study is to evaluate the role of three specific urinary proteins-RhoA, Nerve Growth Factor (NGF), and Brain-Derived Neurotrophic Factor (BDNF)-as potential biomarkers for the diagnosis and follow-up of children aged 4-18 diagnosed with Overactive Bladder (OAB) and Vitamin D deficiency.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Children aged 4-18 years presenting with active OAB symptoms (frequency, urgency)

Disqualifiers

Neurological diseases

Malignancy

Active urinary tract infections

Anatomical bladder anomalies

Trial design

Design model

Parallel

Treatments tested in this trial

Urotherapy
Behavioral
Diagnosis and first-line treatment (urotherapy) will be conducted per European Association of Urology (EAU) guidelines.

Treatment groups

52 Participants

are divided into 2 treatment groups

Group A: Overactive Bladder GroupActive comparator 1 intervention

Group B: Healthy GroupNo intervention 0 interventions

Trial outcomes

Primary outcomes

Changes in Urinary Biomarker Levels: * Quantitative measurement of urinary RhoA, NGF (Nerve Growth Factor), and BDNF (Brain-Derived Neurotrophic Factor) levels using the ELISA method.

Time frame

One year

Secondary outcomes

Clinical Symptom Improvement: * Reduction in LUTS (Lower Urinary Tract Symptoms) based on standardized voiding dysfunction symptom scores.

Time frame

One year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tarik Emre Sener

Lead sponsor

Marmara University

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: